The dynamics of interleukin-6level in HIV-infected patients with herpes zoster
https://doi.org/10.22625/2072-6732-2015-7-2-83-91
Abstract
Interleukin-6 plays a central role in antiviral immunity. However, the function of this cytokine in the pathogenesis of herpes zoster is unknown.
The objective of this study was todeterminethe dynamicsof serum interleukin-6 level in HIV-infected patients with herpes zoster.
55 patients with herpes zoster (30 HIV-positive and 25 HIV-negative) were included. Serum interleukin-6 levels were measured before acyclovir treatment, on the 3rd day of treatment and after healing of skin lesions. The clinical course and dynamics of laboratory data were also evaluated.
The study showed that elevated serum levels of interleukin-6 were associated with HIV-positive status, severity of rash, fever anddecreaseof CD4-lymphocytes. Levels of interleukin-6 in HIV-infected patients were significantly reduced during herpes zoster treatment and reached the level of HIVnegative cohort.Interleukin-6 levels in complicated course of herpes zoster in HIV-infected patients with low CD4-lymphocyte count (less than 350 cells/ml) were significantly higher compared to levels in uncomplicated course of the disease.
About the Authors
A. L. Yakubenko
Saint Petersburg State University, Saint-Petersburg, Russi
Russian Federation
Russian Federation
A. A. Yakovlev
Saint Petersburg State University, Saint-Petersburg, Russi
Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia
Russian Federation
Russian Federation
V. B. Musatov
Saint Petersburg State University, Saint-Petersburg, Russi
Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia
Russian Federation
Russian Federation
Z. N. Kingo
Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia
Russian Federation
Russian Federation
I. V. Gorbova
Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia
Russian Federation
Russian Federation
I. L. Andreeva
Clinical Infectious Diseases Hospital named after S.P. Botkin, Saint-Petersburg, Russia
Russian Federation
Russian Federation
A. Ya. Komarova
Saint Petersburg State University, Saint-Petersburg, Russi
Russian Federation
Russian Federation
References
1. ShakhaninaI.L.,VoroninE.V., MikheevaI.V., et al. Epidemiologia i infekcionnye bolezni. Aktual’nye voprosy. 2011;3:24 (in Russian).
2. Pierik JG, Gumbs PD, Fortanier SA, et al. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect. Dis. 2012 May 10;12:110.
3. Gonzalez Chiappe S, Sarazin M, Turbelin C, et al. Herpes zoster: Burden of disease in France. Vaccine. 2010 Nov 23;28(50):7933-8.
4. Stepanova E.V.VICH-infekciya i immunosupressii. 2009; 1(2):16-30 (in Russian).
5. Gershon AA, Gershon MD, Breuer J, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J. Clin. Virol. 2010 May;48Suppl 1:S2-7.
6. Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J. Infect. Dis. 2002 Oct 15;186Suppl 1:S91-8.
7. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295.
8. Wang JP, Kurt-Jones EA, Shin OS, et al. Varicella-zoster virus activates inflammatory cytokines in human monocytes and macrophages via Toll-like receptor 2. J. Virol. 2005 Oct;79(20):12658-66.
9. Human Immunodeficiency Virus: Medicine. EditedbyN.A. Belyakov, A.G. Rakhmanova. Saint-Petersburg: Baltic Medical Educational Center; c2010. 752 p.(in Russian).
10. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J. Infect. Dis. 2010 Jun 15;201(12):1796-805.
11. Birx DL, Redfield RR, Tencer K, et al. Induction of interleukin-6 during human immunodeficiency virus infection. Blood. 1990 Dec 1;76(11):2303-10.
12. Grob P, Schijns VE, van den Broek MF, et al. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J Virol. 1999 Jun;73(6):4748-54.
13. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994 Mar 24;368(6469):339-42.
14. Farkas G, Marton J, Nagy Z, et al. Experimental acute pancreatitis results in increased blood-brain barrier permeability in the rat: a potential role for tumor necrosis factor and interleukin 6. Neurosci. Lett. 1998 Feb 20;242(3):147-50.
15. Ogata M, Satou T, Kawano R, et al. Correlations of HHV6 viral load and plasma IL-6 concentration with HHV-6 encephalitis in allogeneic stem cell transplant recipients. Bone Marrow Transplant. 2010 Jan;45(1):129-36.
16. Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology. 2001 Jul 24;57(2):295-9.
17. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008 Nov 15;112(10):395964.
18. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med. 2002 Apr;31(4):196-203.
19. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 1;97(1):256-63.
20. Seymour JF, Talpaz M, Cabanillas F, et al. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995 Mar;13(3):575-82.
21. Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J. Surg. Oncol. 2011 Feb 6;9:18.
22. Mastorakos G, Ilias I. Interleukin-6: a cytokine and/or a major modulator of the response to somatic stress. Ann. N. Y. Acad. Sci. 2006 Nov;1088:373-81.
23. Lin ZQ, Kondo T, Ishida Y, et al. Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice. J Leukoc Biol. 2003 Jun;73(6):713-21.
24. Gallucci RM, Simeonova PP, Matheson JM, et al. Impaired cutaneous wound healing in interleukin-6 – deficient and immunosuppressed mice. FASEB J. 2000 Dec;14(15):252531.
25. Turksen K, Kupper T, Degenstein L, et al. идр. Interleukin 6: insights to its function in skin by overexpression in transgenic mice. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5068-72.
26. Hung CC, Hsiao CF, Wang JL, et al. Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Int J STD AIDS. 2005 Oct;16(10):673-6.
27. Weinberg A, Huang S, Song LY, et al. Immune correlates of herpes zoster in HIV-infected children and youth. J. Virol. 2012 Mar;86(5):2878-81.
28. Ku CC, Padilla JA, Grose C, et al. Tropism of varicellazoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol. 2002 Nov;76(22):11425-33.
29. Moffat JF, Stein MD, Kaneshima H, Arvin AM. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol. 1995 Sep;69(9):5236-42.
30. Weinberg A, Wiznia AA, LaFleur BJ, et al. VaricellaZoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2004 Jul 15;190(2):267-70.
31. Van de Perre P, Segondy M, Foulongne V et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet. Infect. Dis. 2008 Aug;8(8):490-7.
32. McMahon MA, Parsons TL, Shen L, et al. Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. J. Virol. 2011 May;85(9):4618-22.
33. Baeten JM, Lingappa J, Beck I, et al. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. J. Infect. Dis. 2011 Jan 1;203(1):117-21.
34. Verjans GM, Boucher CA. Aciclovir for dual infection with HIV and HSV. Lancet. Infect. Dis. 2012Jun;12(6):424-5.
35. Quinlivan ML, Ayres KL, Kelly PJ, et al. Persistence of varicella-zoster virus viraemia in patients with herpes zoster. J. Clin. Virol. 2011 Feb;50(2):130-5.
36. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin. Infect. Dis. 1995 Aug;21(2):370-5.
Review
For citations:
Yakubenko A.L., Yakovlev A.A., Musatov V.B., Kingo Z.N., Gorbova I.V., Andreeva I.L., Komarova A.Ya. The dynamics of interleukin-6level in HIV-infected patients with herpes zoster. Journal Infectology. 2015;7(2):83-91. (In Russ.) https://doi.org/10.22625/2072-6732-2015-7-2-83-91
Views:
1032
.png)
.png)
Email this article 